8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 12, 2003

RENAL CARE GROUP, INC

(Exact Name of Registrant as Specified in Charter)

Delaware	0-27640	62-1622383
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2525 West End Avenue
Suite 600
Nashville, TN 37203
(Address of Principal Executive Offices, including Zip Code)

(615) 345-5500
(Registrant’s telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

TABLE OF CONTENTS

EX-99.1 NEWS RELEASE DATED AUGUST 12, 2003

Item 5.     Other Events.

     On August 12, 2003, Renal Care Group, Inc. (the “Company”) issued a news release announcing that the Board of Directors authorized an extension of its stock repurchase program through December of 2004 and an increase in the plan from $200 million to $250 million. Such news release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 7.     Financial Statements, Pro Forma Financial Information and Exhibits.

(a)	None.
(b)	None.
(c)	Exhibits:

99.1 News Release dated August 12, 2003.

-2-

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	RENAL CARE GROUP, INC.
	By: /s/ R. Dirk Allison R. Dirk Allison Executive Vice President
Dated: August 12, 2003

-3-

INDEX TO EXHIBITS

EXHIBIT NO.	DESCRIPTION
99.1	News Release issued August 12, 2003, regarding an extension of the Company’s stock repurchase program and an increase in the authorized amount to $250 million.

-4- EX-99.1 3 g84574exv99w1.txt EX-99.1 NEWS RELEASE DATED AUGUST 12, 2003 EXHIBIT 99.1 [RENAL CARE GROUP LOGO] NEWS RELEASE CONTACT: R. DIRK ALLISON CHIEF FINANCIAL OFFICER 615-345-5500 RENAL CARE GROUP EXTENDS STOCK REPURCHASE PROGRAM AND INCREASES AMOUNT TO $250 MILLION Nashville, Tennessee, (August 12, 2003) -- Renal Care Group, Inc. (NYSE:RCI) today announced that its Board of Directors authorized an extension of its stock repurchase program through December 2004 and an increase in the plan from $200 million to $250 million. The Board of Directors previously increased the authorized amount under the repurchase program from $100 million to $200 million in November 2002. Through August 8, 2003, the Company had repurchased $111.8 million of its common stock under the repurchase program, leaving $138.2 million available for further repurchases prior to December 2004. The Company intends to repurchase its stock from time to time at prices prevailing in the market or in privately negotiated transactions on conditions acceptable to the Company. The actual number of shares repurchased, the timing of purchases and the price paid will be at the Company's discretion and will depend on market conditions and other relevant factors. Repurchased shares are held in Renal Care Group's treasury and will be available for resale and for general corporate purposes. As of August 8, 2003, the Company had approximately 49.1 million common shares outstanding, net of 3.5 million shares held in treasury. Renal Care Group, Inc. is a specialized dialysis services company that provides care to patients with kidney disease. The Company treats over 21,100 patients at more than 270 owned outpatient dialysis facilities, in addition to providing acute dialysis services at approximately 120 hospitals. Over 6,500 associates provide services across the Company's 27-state network. More information about Renal Care Group, Inc. may be found at www.renalcaregroup.com. Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are usually preceded by words like expect, plan, intend, will and the like, include statements regarding our financial outlook for 2003 and any other statements that necessarily depend on future events. These forward-looking statements reflect management's expectations and are based upon currently available information. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Renal Care Group to differ materially from those expressed in or implied by the forward-looking statements, including risks related to: compliance with health care and other applicable laws; changes in the Medicare and Medicaid programs; risks related to the drug Epogen (EPO); payment reductions by private insurers, hospitals or managed care organizations; the integration of acquired companies; executive succession and dependence on executive officers; and changes in the health care delivery, financing or reimbursement systems. These and other factors affecting the Company are discussed in more detail in Renal Care Group's reports filed with the Securities and Exchange Commission, including without limitation Renal Care Group's most recent annual report on Form 10-K and any quarterly reports on Form 10-Q filed after that annual report. Copies of these filings are available from Renal Care Group upon request. -END- -----END PRIVACY-ENHANCED MESSAGE-----

EX-99.1

                                                                    EXHIBIT 99.1

[RENAL CARE GROUP LOGO]

                                  NEWS RELEASE


CONTACT:   R. DIRK ALLISON
           CHIEF FINANCIAL OFFICER
           615-345-5500

                RENAL CARE GROUP EXTENDS STOCK REPURCHASE PROGRAM
                      AND INCREASES AMOUNT TO $250 MILLION

Nashville, Tennessee, (August 12, 2003) -- Renal Care Group, Inc. (NYSE:RCI)
today announced that its Board of Directors authorized an extension of its stock
repurchase program through December 2004 and an increase in the plan from $200
million to $250 million. The Board of Directors previously increased the
authorized amount under the repurchase program from $100 million to $200 million
in November 2002. Through August 8, 2003, the Company had repurchased $111.8
million of its common stock under the repurchase program, leaving $138.2 million
available for further repurchases prior to December 2004.

         The Company intends to repurchase its stock from time to time at prices
prevailing in the market or in privately negotiated transactions on conditions
acceptable to the Company. The actual number of shares repurchased, the timing
of purchases and the price paid will be at the Company's discretion and will
depend on market conditions and other relevant factors. Repurchased shares are
held in Renal Care Group's treasury and will be available for resale and for
general corporate purposes. As of August 8, 2003, the Company had approximately
49.1 million common shares outstanding, net of 3.5 million shares held in
treasury.

         Renal Care Group, Inc. is a specialized dialysis services company that
provides care to patients with kidney disease. The Company treats over 21,100
patients at more than 270 owned outpatient dialysis facilities, in addition to
providing acute dialysis services at approximately 120 hospitals. Over 6,500
associates provide services across the Company's 27-state network. More
information about Renal Care Group, Inc. may be found at www.renalcaregroup.com.

         Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements, which are usually preceded by words
like expect, plan, intend, will and the like, include statements regarding our
financial outlook for 2003 and any other statements that necessarily depend on
future events. These forward-looking statements reflect management's
expectations and are based upon currently available information. These
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause actual results, performance or achievements of
Renal Care Group to differ materially from those expressed in or implied by the
forward-looking statements, including risks related to: compliance with health
care and other applicable laws; changes in the Medicare and Medicaid programs;
risks related to the drug Epogen (EPO); payment reductions by private insurers,
hospitals or managed care organizations; the integration of acquired companies;
executive succession and dependence on executive officers; and changes in the
health care delivery, financing or reimbursement systems. These and other
factors affecting the Company are discussed in more detail in Renal Care Group's
reports filed with the Securities and Exchange Commission, including without
limitation Renal Care Group's most recent annual report on Form 10-K and any
quarterly reports on Form 10-Q filed after that annual report. Copies of these
filings are available from Renal Care Group upon request.

                                      -END-